During the corresponding time, Fulgent Genetics Inc recorded a revenue increase by 4.86 % year on year, sequentially revenue grew by 21.14 %. While revenue at the Fulgent Genetics Inc 's corporate clients
Fulgent Genetics Inc's Comment on Sales, Marketing and Customers
The company offers anatomic pathology testing services in gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology through CLIA-licensed laboratories in the United States. Its precision diagnostics include next-generation sequencing (NGS) for biopharma research and clinical testing for rare diseases, hereditary cancer, reproductive health, and other disease subtypes. Specialized oncology services encompass flow cytometry, cytogenetic analysis, FISH, immunohistochemistry, molecular genetics, NGS, and consultations in hematopathology and surgical pathology. The company provides BioPharma services to pharmaceutical and biotech companies, contract research organizations (CROs), and sponsored testing programs. It also operates Picture, a telemedicine platform that enables consumers to initiate testing and access clinical support for identifying health markers. Its Therapeutic Development Business, Fulgent Pharma, develops nano-drug delivery platform technology for water insoluble or poorly soluble drugs, supporting intravenous and oral formulations. Customers and markets include Fulgent Pharma Holdings, Inc.
A Strategic Synergy: Fulgent Pharma and Moffitt Cancer Center Join Forces in the Fight Against Cancer In a landmark move poised to dramatically influence the future of cancer treatment, Moffitt Cancer Center and Fulgent Pharma have announced a strategic partnership designed to push the boundaries of cancer therapeutics. Moffitt Cancer Center, a globally recognized leader in cancer care and research, is teaming up with Fulgent Pharma, the innovative nanobiotechnology arm of Fulgent Genetics, Inc. (NASDAQ: FLGT).This coalition between Moffitt Cancer Center and Fulgent Pharma signals an ambitious endeavor to advance the clinical and pre-clinical development of pioneering cancer treatment modalities. By merging ...
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsTAMPA, Fla. and LOS ANGELES - Moffitt Cancer Center, a renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc., have recently announced a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration aims to leverage Moffitt s cutting-edge clinical capabilities along with Fulgent Pharma s expertise in innovative cancer therapeutics.Moffitt Cancer Center is globally recognized for its commitment to research, patient care, and discovery. With a strong focus on personalized medicine, the...
Fulgent Genetics Inc’s Comment on Sales, Marketing and Customers
The company offers anatomic pathology testing services in gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology through CLIA-licensed laboratories in the United States. Its precision diagnostics include next-generation sequencing (NGS) for biopharma research and clinical testing for rare diseases, hereditary cancer, reproductive health, and other disease subtypes. Specialized oncology services encompass flow cytometry, cytogenetic analysis, FISH, immunohistochemistry, molecular genetics, NGS, and consultations in hematopathology and surgical pathology. The company provides BioPharma services to pharmaceutical and biotech companies, contract research organizations (CROs), and sponsored testing programs. It also operates Picture, a telemedicine platform that enables consumers to initiate testing and access clinical support for identifying health markers. Its Therapeutic Development Business, Fulgent Pharma, develops nano-drug delivery platform technology for water insoluble or poorly soluble drugs, supporting intravenous and oral formulations. Customers and markets include Fulgent Pharma Holdings, Inc.
Sources:
Fulgent Genetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Fulgent Genetics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Fulgent Genetics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
83.31 %